09:33 AM EST - Aptose Biosciences Inc. : Announced that clinical data for HM43239, a myeloid kinome inhibitor in-licensed by Aptose is being presented in an oral presentation at the 63rd American Society of Hematology Annual Meeting and Exposition, being held Saturday, December 11 – Monday, December 14 in Atlanta, and virtually. Aptose Biosciences Inc.
shares T.APS are trading unchanged at $3.03.
